Importantly, this combination therapy led to increased CD8+ T-cell infiltration, decreased regulatory T-cells, and reduced exhaustion markers on CD8+ T-cells, suggesting enhanced anti-tumor immunity. The gene discussed is CD8A; the disease is neoplasm.